Take a trial of UK to unlock this pageFind out more

Momentum
Relative Strength (%)
1m
3m
1yr
Volume Change (%)
10d v 3m
Price vs... (%)
52w High
50d MA
200d MA
vs.
market
vs.
industry
Growth & Value

Margin of Safety (beta)
Screens Passed 2
Balance Sheet · Income Statement · Cashflow Financial Summary
Year End 31st Dec 2009 2010 2011 2012 2013 2014 2015E 2016E CAGR / Avg
Revenue $m
Operating Profit $m
Net Profit $m
EPS Reported $
EPS Normalised $
EPS Growth %
PE Ratio x
PEG x
Profitability
Operating Margin %
ROA %
ROCE %
ROE %
Cashflow
Op. Cashflow ps $
Capex ps $
Free Cashflow ps $
Last ex-div: 19th Feb, paid: 23rd Mar more... Dividends
Dividend ps $
Dividend Growth %
Dividend Yield %
Dividend Cover x
Balance Sheet
Cash etc $m
Working Capital $m
Net Fixed Assets $m
Net Debt $m
Book Value $m
Average Shares m
Book Value ps $ +1.8%

FINANCIAL BRIEF: For the fiscal year ended 31 December 2014, AstraZeneca plc revenues increased 1% to $26.1B. Net income decreased 52% to $1.23B. Revenues reflect China segment increase of 21% to $2.23B, United States segment increase of 3% to $10.49B, Sweden segment increase of 26% to $508M. Net income was offset by Continental Europe segment income decrease of 42% to $1.78B, United Kingdom segment loss increase from $171M to $851M. more »

Health Trend

Bankruptcy Risk

  Earnings Manipulation Risk

Magic Formula Score
C+
C+

Other Ratios
Leverage (ttm) Total Ex Intang
Gross Gearing %
Net Gearing %
Cash / Assets %

vs.
market
vs.
industry
Recent History
Latest interim period (ended 31st Dec '14) vs. prior year
Sales Growth %
EPS Growth %
3yr Compound Annual Growth Rate
Sales Growth %
EPS Growth %
DPS Growth %

Broker Forecasts
31st Dec 2015
31st Dec 2016

Price Target: $73.9 (+6.11% above Price) Net Profit EPS DPS Net Profit EPS DPS
Est. Long Term Growth Rate: -1.3% ($) (¢) (¢) ($) (¢) (¢)
Consensus Estimate
1m Change
3m Change
28 brokers Broker Consensus Trend
Broker Recommendations for AstraZeneca
Recommendation:Strong SellSellHoldBuyStrong Buy
No. of Analysts: 6 4 12 4 5

Named Brokers and Analysts
Jefferies Jeffrey Holford , Credit Suisse Matthew Weston , SEB Equities Lars Hevreng , Leerink Partners LLC Seamus Fernandez , Sanford Bernstein Tim Anderson , Danske Markets Martin Parkhøi Mattias Häggblom Thomas Bowers , Seymour Pierce , Panmure Gordon Savvas Neophytou , Natixis Philippe Lanone Jean-Jacques Le Fur , Mirabaud Securities Nicholas Turner , Swedbank Markets Johan Unnerus , Nordea Markets Erik Hultgård , Davy , CA Cheuvreux , Societe Generale , Handelsbanken Capital Markets Peter Sehested , Pareto Securities AS Yilmaz Mahshid , Berenberg Alistair Campbell , DZ Bank , Helvea SA Odile Rundquist , Kepler Cheuvreux Sheela Sharma , Charles Stanley Rae Ellingham , Shore Capital Stockbrokers Brian White , Bryan Garnier Eric Le Berrigaud , Morningstar, Inc. Damien Conover , Day by Day Valérie GASTALDY , Landesbank Baden-Wuerttemberg Timo Kuerschner , Liberum Naresh Chouhan , Baader Helvea Equity Research Odile Rundquist ,

Profile Summary

AstraZeneca PLC is the United Kingdom-based global biopharmaceutical company. AstraZeneca discovers, develops and commercializes prescription medicines for six areas of healthcare: Cardiovascular, Gastrointestinal, Infection, Neuroscience, Oncology, and Respiratory and Inflammation. It has a range of medicines that includes treatments for illnesses, such as its antibiotic, Merrem/Meronem and Losec/Prilosec for acid related diseases. AstraZeneca’s products include Crestor, Atacand,Seloken/Toprol-XL, Plendil, Onglyza, Zestril, Symbicort and Zoladex. The Company owns and operates a range of research and development (R&D), production and marketing facilities across the world. AstraZeneca operates in over 100 countries, including China, Mexico, Brazil and Russia.

Directors: Pascal Soriot (CEO) 55, Marc Dunoyer (CFO) 61, Ruud Dobber (EVP) , Caroline Hempstead (EVP) , Paul Hudson (EVP) , Bahija Jallal (EVP) , Mark Mallon (EVP) , Briggs Morrison (EVP) , Menelas Pangalos (EVP) , David Smith (EVP) , Leif Johansson (NEC) 66, John Varley (NED) 59, Genevieve Berger (NED) 60, Ann Cairns (NED) 57, Marcus Wallenberg (NED) 59,

No. of Employees: 57,500 No. of Shareholders: 100,371


Last Annual December 31st, 2014
Last Interim December 31st, 2014
Shares in Issue 1,263,288,333
Free Float 1.26bn (99.7%)

Address 2 Kingdom Street, LONDON, W2 6BD, United Kingdom
Web http://www.astrazeneca.com/
Phone +44 20 76048000
Contact Karl Hard (IR Contact Officer)
Auditors KPMG LLP

AZN Share Price Performance AZN Quote
4686p
-5.0  -0.1%
Traded 5:07pm · Minimum 15 min delayed · NMS: 0.500k

Latest AZN News Announcements (delayed)

Upcoming AZN Events
Friday 24th April, 2015
Q1 2015 AstraZeneca PLC Earnings Release
Friday 24th April, 2015
AstraZeneca PLC Annual Shareholders Meeting
Thursday 30th July, 2015
Q2 2015 AstraZeneca PLC Earnings Release
Thursday 5th November, 2015
Q3 2015 AstraZeneca PLC Earnings Release
Friday 22nd April, 2016 (estimate)
AstraZeneca PLC Annual Shareholders Meeting

Recent ↓
Wednesday 25th March, 2015
AstraZeneca PLC at Biotechnology Industry Organization (BIO) Asia International Conference
Thursday 19th February, 2015
Dividend For AZN.L
Wednesday 18th February, 2015
Dividend For AZN.BA
Wednesday 18th February, 2015
Dividend For AZN
Thursday 5th February, 2015
Full Year 2014 AstraZeneca PLC Earnings Call
Thursday 5th February, 2015
Full Year 2014 AstraZeneca PLC Earnings Release
Wednesday 14th January, 2015
AstraZeneca PLC at JPMorgan Healthcare Conference
Tuesday 18th November, 2014
AstraZeneca PLC Investor Day
Thursday 6th November, 2014
Q3 2014 AstraZeneca PLC Earnings Call
Thursday 6th November, 2014
Q3 2014 AstraZeneca PLC Earnings Release


Use of our data service is subject to express Terms of Service. Please see our full site disclaimer for more details. In particular, it is very important to do your own research (DYOR) and seek professional advice before making any investment based on your own personal circumstances. Please note that the information, data and analysis contained within this stock report: (a) include the proprietary information of Stockopedia's third party licensors and Stockopedia; (b) should not be copied or redistributed except as specifically authorised; and (c) are not warranted to be complete, accurate or timely. You should independently research and verify any information that you find in this report. Stockopedia will not be liable in respect of any loss, trading or otherwise, that you may suffer arising out of such information or any reliance you may place upon it. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up. © Stockopedia 2015.


Should you buy AZN

Access AZN Analytics Now!

FREE TRIAL or TAKE THE TOUR